Reaching High-Risk Patients for HIV Preexposure Prophylaxis

被引:3
作者
Riddell, James [1 ]
Cohn, Jonathan A. [2 ]
机构
[1] Univ Michigan Hlth Syst, Div Infect Dis, Ann Arbor, MI USA
[2] Wayne State Univ, Sch Med, Div Infect Dis, Detroit, MI USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2016年 / 316卷 / 02期
关键词
UNITED-STATES; CARE;
D O I
10.1001/jama.2016.9128
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
IMPORTANCE Several randomized clinical trials have demonstrated the efficacy of preexposure prophylaxis (PrEP) in preventing human immunodeficiency virus (HIV) acquisition. Little is known about adherence to the regimen, sexual practices, and overall effectiveness when PrEP is implemented in clinics that treat sexually transmitted infections (STIs) and community-based clinics serving men who have sex with men (MSM). OBJECTIVE To assess PrEP adherence, sexual behaviors, and the incidence of STIs and HIV infection in a cohort of MSM and transgender women initiating PrEP in the United States. DESIGN, SETTING, AND PARTICIPANTS Demonstration project conducted from October 1, 2012, through February 10, 2015 (last date of follow-up), among 557 MSM and transgender women in 2 STI clinics in San Francisco, California, and Miami, Florida, and a community health center in Washington, DC. Data were analyzed from December 18, 2014, through August 8, 2015. INTERVENTIONS A combination of daily, oral tenofovir disoproxil fumarate and emtricitabine was provided free of charge for 48 weeks. All participants received HIV testing, brief client-centered counseling, and clinical monitoring. MAIN OUTCOMES AND MEASURES Concentrations of tenofovir diphosphate in dried blood spot samples, self-reported numbers of anal sex partners and episodes of condomless receptive anal sex, and incidence of STI and HIV acquisition. RESULTS Overall, 557 participants initiated PrEP, and 437 of these (78.5%) were retained through 48 weeks. Based on the findings from the 294 participants who underwent measurement of tenofovir diphosphate levels, 80.0% to 85.6% had protective levels (consistent with >= 4 doses/wk) at follow-up visits. African American participants (56.8% of visits; P = .003) and those from the Miami site (65.1% of visits; P < .001) were less likely to have protective levels, whereas those with stable housing (86.8%; P = .02) and those reporting at least 2 condomless anal sex partners in the past 3 months (88.6%; P = .01) were more likely to have protective levels. The mean number of anal sex partners declined during follow-up from 10.9 to 9.3, whereas the proportion engaging in condomless receptive anal sex remained stable at 65.5% to 65.6%. Overall STI incidence was high (90 per 100 person-years) but did not increase over time. Two individuals became HIV infected during follow-up (HIV incidence, 0.43 [95% CI, 0.05-1.54] infections per 100 person-years); both had tenofovir diphosphate levels consistent with fewer than 2 doses/wk at seroconversion. CONCLUSIONS AND RELEVANCE The incidence of HIV acquisition was extremely low despite a high incidence of STIs in a large US PrEP demonstration project. Adherence was higher among those participants who reported more risk behaviors. Interventions that address racial and geographic disparities and housing instability may increase the impact of PrEP.
引用
收藏
页码:211 / +
页数:2
相关论文
共 7 条
  • [1] Bradley H, 2014, MMWR-MORBID MORTAL W, V63, P1113
  • [2] Franks J, 2015, 8 IAS INT AIDS SOC C
  • [3] Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study
    Grant, Robert M.
    Anderson, Peter L.
    McMahan, Vanessa
    Liu, Albert
    Amico, K. Rivet
    Mehrotra, Megha
    Hosek, Sybil
    Mosquera, Carlos
    Casapia, Martin
    Montoya, Orlando
    Buchbinder, Susan
    Veloso, Valdilea G.
    Mayer, Kenneth
    Chariyalertsak, Suwat
    Bekker, Linda-Gail
    Kallas, Esper G.
    Schechter, Mauro
    Guanira, Juan
    Bushman, Lane
    Burns, David N.
    Rooney, James F.
    Glidden, David V.
    [J]. LANCET INFECTIOUS DISEASES, 2014, 14 (09) : 820 - 829
  • [4] Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men.
    Grant, Robert M.
    Lama, Javier R.
    Anderson, Peter L.
    McMahan, Vanessa
    Liu, Albert Y.
    Vargas, Lorena
    Goicochea, Pedro
    Casapia, Martin
    Guanira-Carranza, Juan Vicente
    Ramirez-Cardich, Maria E.
    Montoya-Herrera, Orlando
    Fernandez, Telmo
    Veloso, Valdilea G.
    Buchbinder, Susan P.
    Chariyalertsak, Suwat
    Schechter, Mauro
    Bekker, Linda-Gail
    Mayer, Kenneth H.
    Kallas, Esper Georges
    Amico, K. Rivet
    Mulligan, Kathleen
    Bushman, Lane R.
    Hance, Robert J.
    Ganoza, Carmela
    Defechereux, Patricia
    Postle, Brian
    Wang, Furong
    McConnell, J. Jeff
    Zheng, Jia-Hua
    Lee, Jeanny
    Rooney, James F.
    Jaffe, Howard S.
    Martinez, Ana I.
    Burns, David N.
    Glidden, David V.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (27) : 2587 - 2599
  • [5] Hosek S, 2015, 8 IAS INT AIDS SOC C
  • [6] Preexposure Prophylaxis for HIV Infection Integrated With Municipal- and Community-Based Sexual Health Services
    Liu, Albert Y.
    Cohen, Stephanie E.
    Vittinghoff, Eric
    Anderson, Peter L.
    Doblecki-Lewis, Susanne
    Bacon, Oliver
    Chege, Wairimu
    Postle, Brian S.
    Matheson, Tim
    Amico, K. Rivet
    Liegler, Teri
    Rawlings, M. Keith
    Trainor, Nikole
    Blue, Robert Wilder
    Estrada, Yannine
    Coleman, Megan E.
    Cardenas, Gabriel
    Feaster, Daniel J.
    Grant, Robert
    Philip, Susan S.
    Elion, Richard
    Buchbinder, Susan
    Kolber, Michael A.
    [J]. JAMA INTERNAL MEDICINE, 2016, 176 (01) : 75 - 84
  • [7] Human Immunodeficiency Virus Transmission at Each Step of the Care Continuum in the United States
    Skarbinski, Jacek
    Rosenberg, Eli
    Paz-Bailey, Gabriela
    Hall, H. Irene
    Rose, Charles E.
    Viall, Abigail H.
    Fagan, Jennifer L.
    Lansky, Amy
    Mermin, Jonathan H.
    [J]. JAMA INTERNAL MEDICINE, 2015, 175 (04) : 588 - 596